Investigational Cell Therapy Bemdaneprocel Shows Sustained Safety and Promising Motor Improvements at 36 Months in Parkinson’s Disease Trial

Bayer AG and its subsidiary BlueRock Therapeutics LP have announced encouraging 36-month follow-up data from the Phase I exPDite clinical trial of bemdaneprocel (BRT-DA01), an investigational cell therapy aimed at…

Continue Reading Investigational Cell Therapy Bemdaneprocel Shows Sustained Safety and Promising Motor Improvements at 36 Months in Parkinson’s Disease Trial

Parkinson’s: Newly Approved Drug Gives Advanced-Stage Patients Longer Periods of Relief

The FDA’s recent approval of AbbVie’s new combination therapy provides patients with longer-lasting control of movements. As described recently in Biopharmadive, Parkinson’s disease is characterized by uncontrolled muscle movements or…

Continue Reading Parkinson’s: Newly Approved Drug Gives Advanced-Stage Patients Longer Periods of Relief
German Scientists Find Possible Parkinson’s Treatment in Diabetes Drug
Source: Pixabay

German Scientists Find Possible Parkinson’s Treatment in Diabetes Drug

Parkinson’s disease is a degenerative movement disorder of the central nervous system that insidiously forms, even starting subtly with a single tremor, progressing into slurred speech, loss of balance, and…

Continue Reading German Scientists Find Possible Parkinson’s Treatment in Diabetes Drug

Norway Researchers Find Potential New Treatment for Patients with Parkinson’s Risk

Norway scientists Suchi Mittal, et al. have found compounds that reduce levels of a key gene that increases the risk of developing Parkinson's disease. Parkinson's disease is a degenerative central…

Continue Reading Norway Researchers Find Potential New Treatment for Patients with Parkinson’s Risk